uftoral has been researched along with s 1 (combination) in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kouchi, Y; Maeda, Y; Morinaga, H; Ohuchida, A | 1 |
| Taguchi, T | 1 |
| Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M | 1 |
| Ikeda, H; Inokuchi, T; Irie, A; Mizoguchi, Y; Shibahara, K; Takebe, Y; Yamada, K | 1 |
| Hoff, PM | 1 |
| Hasuo, T; Ikeshima, S; Ishihara, K; Iwatsuki, M; Kuramoto, M | 1 |
| Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T | 1 |
| Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M | 1 |
| Aoki, T; Mino, A; Murahashi, K; Nishino, K; Sowa, M; Tachimori, A; Takagaki, K | 1 |
| Komatsu, Y | 1 |
| Cho, H; Hasegawa, S; Kobayashi, O; Osaragi, T; Sairenji, M; Tsuburaya, A; Yoshida, T; Yoshikawa, T | 1 |
| Fukushima, M; Tanaka, F; Wada, H | 1 |
| Arita, M; Kuga, Y; Miwata, T; Moriya, T; Murakami, E; Nishida, T; Numata, Y; Ohya, T; Okanobu, H; Tanaka, T; Yoshimi, S | 1 |
| Kawai, K; Kitayama, J; Nagawa, H; Sunami, E; Yasuda, K | 1 |
| Abe, M; Kiniwa, M; Matsuo, K; Nakagawa, F; Noguchi, S; Nukatsuka, M; Saito, H; Shibata, J; Uchida, J | 1 |
| Boku, N; Endo, T; Ikejiri, K; Kameoka, S; Kinugasa, Y; Kotake, K; Matsubara, Y; Mochizuki, H; Mochizuki, I; Nakamoto, Y; Shinozaki, H; Sugihara, K; Takagane, A; Takahashi, K; Takahashi, Y; Takii, Y; Takiuchi, H; Tomita, N; Watanabe, M; Watanabe, T | 1 |
| Hwang, SH; Kim, SG | 1 |
5 review(s) available for uftoral and s 1 (combination)
| Article | Year |
|---|---|
[Gastrointestinal cancer and oral anticancer agents].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Drug Combinations; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 2003 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Europe; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Staging; Oxonic Acid; Practice Guidelines as Topic; Rectal Neoplasms; Tegafur; United States; Uracil | 2007 |
UFT and S-1 for treatment of primary lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Resistance, Neoplasm; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Lung Neoplasms; Oxonic Acid; Radiotherapy, Adjuvant; Tegafur; Time Factors; Treatment Outcome; Uracil | 2010 |
1 trial(s) available for uftoral and s 1 (combination)
| Article | Year |
|---|---|
Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Tegafur; Uracil | 2012 |
11 other study(ies) available for uftoral and s 1 (combination)
| Article | Year |
|---|---|
[Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Topics: Animals; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Body Weight; Dose-Response Relationship, Drug; Drug Combinations; Fluorouracil; Immune System; Immune Tolerance; Immunologic Tests; Mice; Mice, Inbred BALB C; Organ Size; Oxonic Acid; Pyridines; Spleen; Tegafur; Thymus Gland; Uracil | 1996 |
[A case report of tongue squamous cell carcinoma showing a complete response to TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Pyridines; Remission Induction; Tegafur; Tongue Neoplasms; Uracil | 2003 |
[A case of unresectable non-small cell lung cancer with pleural dissemination successfully treated with DIF].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Oxonic Acid; Pleural Effusion, Malignant; Pyridines; Quality of Life; Tegafur; Uracil | 2006 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimidine Dehydrogenase Deficiency; Drug Combinations; Fatal Outcome; Humans; Liver Neoplasms; Male; Nausea; Oxonic Acid; Stomach Neoplasms; Tegafur; Uracil | 2006 |
[A case of liver metastasis of gastric cancer undergoing non-curative operation responding completely to combination therapy of S-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur; Uracil | 2007 |
[A case of breast metastasis of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Uracil | 2007 |
[A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2010 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Combinations; Estrogen Receptor alpha; Estrogens; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oxonic Acid; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tegafur; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Uracil | 2011 |
The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Floxuridine; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Uracil | 2016 |